Suven Pharmaceuticals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Sudhir Singh

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.1yrs
이사회 평균 재임 기간	1.2yrs

최근 관리 업데이트

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08

CEO

Sudhir Singh (59 yo)

1.3yrs

테뉴어

Dr. Sudhir Kumar Singh, Ph.D. serves as Chief Executive Officer since September 29, 2023 at Suven Pharmaceuticals Ltd. He served as Chief Operating Officer of Aragen Life Sciences Private Limited from Sept...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vivek Sharma	Executive Chairman	less than a year	데이터 없음	데이터 없음
Sudhir Singh	Chief Executive Officer	1.3yrs	데이터 없음	데이터 없음
Himanshu Agarwal	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Cyndrella Carvalho	Head of Investor Relations	no data	데이터 없음	데이터 없음
Kundan Jha	Company Secretary & Compliance Officer	less than a year	데이터 없음	데이터 없음
Gaurav Bahadur	Chief Human Resources Officer	1.3yrs	데이터 없음	데이터 없음
Vetukuri Venkata Naga Kali Vara Raju	MD & Director	no data	데이터 없음	데이터 없음
Subba Komaravolu	Chief Strategy Officer	1.3yrs	데이터 없음	데이터 없음
Declan Ryan	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음
Sunder Venkatraman	Vice President of Corporate Affairs	3.9yrs	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: SUVENPHAR 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vivek Sharma	Executive Chairman	less than a year	데이터 없음	데이터 없음
Vetukuri Venkata Naga Kali Vara Raju	MD & Director	1.3yrs	데이터 없음	데이터 없음
Abhijit Mukherjee	Member of Advisory Council	1.2yrs	데이터 없음	데이터 없음
Venkateswarlu Jasti	Member of Advisory Council	less than a year	₹68.35m	데이터 없음
Shweta Jalan	Non-Executive Director	1.1yrs	데이터 없음	데이터 없음
Pankaj Patwari	Non-Executive Director	1.3yrs	데이터 없음	데이터 없음
Vinod Rao	Independent Director	1.3yrs	₹1.36m	데이터 없음
Matangi Gowrishankar	Independent Director	1.3yrs	₹1.36m	데이터 없음
Stefan Stoffel	Member of Advisory Council	1.2yrs	데이터 없음	데이터 없음
Pravin Udhyavara Rao	Independent Director	1.1yrs	₹1.07m	데이터 없음
Vaidheesh Annaswamy	Vice-Chairperson of Advisory Council	less than a year	₹27.27m	데이터 없음
Kumarapuram Ananthakrishnan	Independent Director	1.3yrs	₹1.36m	0.000050% ₹ 150.8k

1.2yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: SUVENPHAR 의 이사회는 경험(평균 재직 기간 1.2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 21:34
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Suven Pharmaceuticals Limited 4 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Nikhil Shetty	BP Wealth Management Private Limited
Vinod T.P.	Geojit Financial Services Ltd.

Suven Pharmaceuticals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Suven Pharmaceuticals Limited Announces the Resignation of Brian Shaughnessy as Chief Commercial Officer and Senior Management Personnel

Suven Pharmaceuticals Limited Announces Board Changes

Suven Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Suven Pharmaceuticals Limited Announces CFO Changes

Recent updates

Price target increased by 51% to ₹1,435

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire an unknown minority stake in NJ BIO, Inc. for $49.4 million.

New major risk - Revenue and earnings growth

Second quarter 2025 earnings released: EPS: ₹3.23 (vs ₹3.13 in 2Q 2024)

Suven Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 12, 2024

Suven Pharmaceuticals Limited Announces the Resignation of Brian Shaughnessy as Chief Commercial Officer and Senior Management Personnel

Suven Pharmaceuticals Limited Announces Board Changes

Suven Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Suven Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Investor sentiment improves as stock rises 18%

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire 67.50% stake in Sapala Organics Private Limited for INR 2.3 billion.

Full year 2024 earnings released: EPS: ₹11.80 (vs ₹16.16 in FY 2023)

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire Cohance Lifesciences Limited.

Consensus revenue estimates fall by 14%

Price target increased by 17% to ₹710

Third quarter 2024 earnings released: EPS: ₹1.84 (vs ₹4.23 in 3Q 2023)

Suven Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Suven Pharmaceuticals Limited Announces CFO Changes

Suven Pharmaceuticals Limited Announces CFO Changes

Suven Pharmaceuticals Limited Appoints Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju as Managing Director

Suven Pharmaceuticals Limited Approves Interim Dividend for the Financial Year 2023-24

Suven Pharmaceuticals Limited Proposes Interim Dividend for the Financial Year 2022-23

Second quarter 2024 earnings released: EPS: ₹3.13 (vs ₹2.83 in 2Q 2023)

Suven Pharmaceuticals Limited, Annual General Meeting, Dec 15, 2023

Suven Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 09, 2023

First quarter 2024 earnings released: EPS: ₹4.74 (vs ₹4.22 in 1Q 2023)

Suven Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Insider recently sold ₹3.4m worth of stock

Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹6.29 in 3Q 2022)

Advent International Corporation agreed to acquire 50.1% stake in Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) from Jasti Family for INR63 billion.

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

High number of new directors

Second quarter 2023 earnings released: EPS: ₹2.83 (vs ₹3.81 in 2Q 2022)

Blackstone, Advent Reportedly to Buy Stake in Suven Pharma

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Full year 2022 earnings: EPS exceeds analyst expectations

Suven Pharmaceuticals Limited to Report Q4, 2023 Results on May 15, 2023

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 18, 2022

Suven Pharmaceuticals Limited to Report Q4, 2022 Results on May 09, 2022

High number of new and inexperienced directors

Suven Pharmaceuticals Limited (BSE:543064) agreed to acquire Casper Pharma Private Limited for approximately $20 million.

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Investor sentiment improved over the past week

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Suven Pharmaceuticals to Evaluate the Acquisition Opportunity of Casper Pharma

Suven Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 08, 2022

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Second quarter 2022 earnings released: EPS ₹3.81 (vs ₹2.91 in 2Q 2021)

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Full year 2021 earnings released: EPS ₹14.23 (vs ₹12.45 in FY 2020)

Upcoming dividend of ₹1.00 per share

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Price target increased to ₹572

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Full year 2021 earnings released: EPS ₹14.23 (vs ₹12.45 in FY 2020)

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

New 90-day high: ₹507

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Suven Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 10, 2021

Blackstone, CVC & Warburg Reportedly in Race to Buy Suven Pharma

New 90-day high: ₹503